1
|
Daigmorte C, Usturoi D, Fournier C, Wallyn F, Lorut C, Héluain V, Mazières J, Legodec J, Escarguel B, Egenod T, Cellerin L, Favrolt N, Lachkar S, Crutu A, Briault A, Gut-Gobert C, Bourinet V, Camuset J, Loïc P, Schlossmacher P, Porzio M, Luchez A, Vergnon JM, Pajiep Chapda MC, Roy P, Dutau H, Guibert N. Therapeutic bronchoscopy for malignant central airway obstructions caused by non-bronchogenic cancers: Results from the EpiGETIF registry. Respirology 2024. [PMID: 38634359 DOI: 10.1111/resp.14723] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2024] [Accepted: 04/02/2024] [Indexed: 04/19/2024]
Abstract
BACKGROUND AND OBJECTIVE Little is known about malignant central airway obstruction (MCAO) complicating the metastatic spread of non-bronchogenic solid cancers (NBC) and their bronchoscopic management. This study aimed to describe the epidemiology of this population and determine prognostic factors before therapeutic bronchoscopy (TB). METHODS In this multicenter study using the EpiGETIF registry, we analysed patients treated with TB for MCAO caused by NBC between January 2019 and December 2022. RESULTS From a database of 2389 patients, 436 patients (18%) with MCAO and NBC were identified. After excluding patients with direct local invasion, 214 patients (8.9%) were analysed. The main primaries involved were kidney (17.8%), colon (16.4%), sarcoma (15.4%), thyroid (8.9%) and head and neck (7.9%) cancers. Most patients (63.8%) had already received one or more lines of systemic treatment. Obstructions were purely intrinsic in 58.2%, extrinsic in 11.1% and mixed in 30.8%. Mechanical debulking was used in 73.4% of cases, combined with thermal techniques in 25.6% of cases. Airway stenting was required in 38.4% of patients. Median survival after TB was 11.2 months, influenced by histology (p = 0.002), performance status (p = 0.019), initial hypoxia (HR 1.45 [1.01-2.18]), prior oncologic treatment received (HR 1.82 [1.28-2.56], p < 0.001) and assessment of success at the end of the procedure (HR 0.66 [0.44-0.99], p < 0.001). Complications rate was 8.8%, mostly mild, with no procedure-related mortality. CONCLUSION TB for MCAO caused by a NBC metastasis provides rapid improvement of symptoms and prolonged survival. Patients should be promptly referred by medical oncologists for bronchoscopic management based on the prognostic factors identified.
Collapse
Affiliation(s)
- Clément Daigmorte
- Pulmonology Department, Toulouse University Hospital, Toulouse, France
| | - Daniela Usturoi
- Thoracic Surgery Department, Foch-Suresnes University Hospital, Paris, France
| | - Clément Fournier
- Pulmonology Department, Heart and Lung Institute, CHU Lille, Lille, France
| | - Frederic Wallyn
- Pulmonology Department, Heart and Lung Institute, CHU Lille, Lille, France
| | - Christine Lorut
- Pulmonology Department, Cochin University Hospital, Paris, France
| | - Valentin Héluain
- Pulmonology Department, Toulouse University Hospital, Toulouse, France
| | - Julien Mazières
- Pulmonology Department, Toulouse University Hospital, Toulouse, France
| | - Julien Legodec
- Pulmonology Department, Saint Joseph Hospital, Marseille, France
| | - Bruno Escarguel
- Pulmonology Department, Saint Joseph Hospital, Marseille, France
| | - Thomas Egenod
- Pulmonology Department, Limoges University Hospital, Limoges, France
| | - Laurent Cellerin
- Pulmonology Department, Nantes University Hospital, Nantes, France
| | - Nicolas Favrolt
- Pulmonology Department, Dijon-Bourgogne University Hospital, Dijon, France
| | - Samy Lachkar
- Pulmonology Department, Rouen University Hospital, Rouen, France
| | - Adrian Crutu
- Pulmonology Department, Marie Lannelongue Hospital, France
| | - Amandine Briault
- Pulmonology Department, Grenoble Alpes University Hospital, Grenoble, France
| | | | - Valerian Bourinet
- Pulmonology Department, Saint Pierre University Hospital, Saint Pierre, France
| | - Juliette Camuset
- Pulmonology Department, Tenon University Hospital, Paris, France
| | - Perrot Loïc
- Pulmonology Department, Institut Mutualiste Montsouris, Paris, France
| | - Pascal Schlossmacher
- Department of Pneumology, University Hospital of La Reunion, Saint Denis, France
| | - Michele Porzio
- Pulmonology Department, Strasbourg University Hospital, Strasbourg, France
| | - Antoine Luchez
- Pulmonology Department, Hôpital privé de la Loire, Saint Etienne, France
| | - Jean-Michel Vergnon
- Pulmonology Department, Saint Etienne University Hospital, Saint Etienne, France
| | - Marie-Christelle Pajiep Chapda
- Pulmonology Department, Toulouse University Hospital, Toulouse, France
- MeDatas, CIC (Centre d'Investigation Clinique), CHU Toulouse, Toulouse, France
| | - Pascalin Roy
- Pulmonology Department, Toulouse University Hospital, Toulouse, France
- Pulmonology Department, Institut Universitaire de Cardiologie et de Pneumologie de, Québec, Québec, Canada
| | - Hervé Dutau
- Pulmonology Department, Marseille Nord University Hospital, Marseille, France
| | - Nicolas Guibert
- Pulmonology Department, Toulouse University Hospital, Toulouse, France
| |
Collapse
|
2
|
Rakotoarisoa L, Weiss L, Lefebvre F, Porzio M, Renaud-Picard B, Ravoninjatovo B, Abely M, Danner-Boucher I, Dubois S, Troussier F, Prevotat A, Rault G, Kessler R, Kessler L. Early glucose abnormalities revealed by continuous glucose monitoring associate with lung function decline in cystic fibrosis: A five-year prospective study. J Diabetes Complications 2024; 38:108703. [PMID: 38430625 DOI: 10.1016/j.jdiacomp.2024.108703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/03/2023] [Revised: 01/22/2024] [Accepted: 02/13/2024] [Indexed: 03/05/2024]
Abstract
BACKGROUND Cystic fibrosis related diabetes (CFRD) is commonly associated with declining lung function and nutritional status. We aimed to evaluate the pulmonary impact of early glucose abnormalities by using 2-h standard oral glucose tolerance testing (OGTT) and continuous glucose monitoring (CGM) in people with cystic fibrosis (PwCF). METHODS PwCF aged ≥10 years old without known CFRD were included in a five-year prospective multicentre study. Annual evaluation of nutritional status, lung function, OGTT and CGM was set up. Associations between annual rate changes (Δ) in lung function, ΔFEV1 (forced expiratory volume in 1 s) percentage predicted (pp) and ΔFVC (forced vital capacity) pp., and annual rate changes in OGTT or CGM variables were estimated with a mixed model with a random effect for subject. RESULTS From 2009 to 2016, 112 PwCF (age: 21 ± 11 years, BMI (body mass index) z-score: -0.55 ± 1.09, FEV1pp: 77 ± 24 %, 2-h OGTT glucose: 122 ± 44 mg/dL, AUC (area under curve) >140 mg/dL: 1 mg/dL/day (0.2, 3.0) were included. A total of 428 OGTTs and 480 CGMs were collected. The participants presented annual decline of FVCpp and FEV1pp at -1.0 % per year (-1.6, -0.4), p < 0.001 and - 1.9 % per year (-2.5, -1.3), p < 0.001 respectively without change in BMI z-score during the study. Variation of two-hour OGTT glucose was not associated with declining lung function, as measured by ΔFEV1pp (p = 0.94) and ΔFVCpp (p = 0.90). Among CGM variables, only increase in AUC >140 mg/dL between two annual visits was associated with a decrease in ΔFVCpp (p < 0.05) and ΔFEV1pp (p < 0.05). CONCLUSIONS This prospective study supports the fact that early glucose abnormalities revealed by CGM predict pulmonary function decline in PwCF, while 2-h standard OGTT glucose is not associated with pulmonary impairment.
Collapse
Affiliation(s)
- Luc Rakotoarisoa
- Department of Endocrinology, Diabetes and Nutrition, Strasbourg University Hospital, France; Adult Cystic Fibrosis Centre, Strasbourg University Hospital, France; UMR Inserm 1260, Regenerative Nanomedicine, University of Strasbourg, France
| | - Laurence Weiss
- Pediatric Cystic Fibrosis Centre, Strasbourg University Hospital, France
| | - François Lefebvre
- Group of Methodology in Clinical Research (GMRC), Strasbourg University Hospital, France
| | - Michele Porzio
- Adult Cystic Fibrosis Centre, Strasbourg University Hospital, France; Department of Pneumology, Strasbourg University Hospital, France
| | - Benjamin Renaud-Picard
- Adult Cystic Fibrosis Centre, Strasbourg University Hospital, France; UMR Inserm 1260, Regenerative Nanomedicine, University of Strasbourg, France; Department of Pneumology, Strasbourg University Hospital, France
| | | | - Michel Abely
- Cystic Fibrosis Centre, Reims University Hospital Centre, France
| | | | | | | | - Anne Prevotat
- Cystic Fibrosis Centre, Lille University Hospital, France
| | - Gilles Rault
- Cystic Fibrosis Centre of Perharidy, Roscoff, France
| | - Romain Kessler
- Adult Cystic Fibrosis Centre, Strasbourg University Hospital, France; UMR Inserm 1260, Regenerative Nanomedicine, University of Strasbourg, France; Department of Pneumology, Strasbourg University Hospital, France
| | - Laurence Kessler
- Department of Endocrinology, Diabetes and Nutrition, Strasbourg University Hospital, France; Adult Cystic Fibrosis Centre, Strasbourg University Hospital, France; UMR Inserm 1260, Regenerative Nanomedicine, University of Strasbourg, France.
| |
Collapse
|
3
|
Dalmonte S, Golinelli P, Oberhofer N, Strocchi S, Rossetti V, Berta L, Porzio M, Angelini L, Paruccini N, Villa R, Bertolini M, Delle Canne S, Cavallari M, D'Ercole L, Guerra G, Rosasco R, Cannillo B, D'Alessio A, Di Nicola E, Origgi D, De Marco P, Maldera A, Scabbio C, Rottoli F, Castriconi R, Lorenzini E, Pasquali G, Pietrobon F, Bregant P, Giovannini G, Favuzza V, Bruschi A, D'Urso D, Maestri D, De Novellis S, Fracassi A, Boschiroli L, Quattrocchi M, Gilio MA, Roberto E, Altabella L, Califano G, Cimmino MC, Bortoli E, Deiana E, Pagan L, Berardi P, Ardu V, Azzeroni R, Campoleoni M, Ravaglia V. Typical values of z-resolution for different Digital Breast Tomosynthesis systems evaluated in a multicenter study. Phys Med 2024; 119:103300. [PMID: 38325222 DOI: 10.1016/j.ejmp.2024.103300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/27/2023] [Revised: 12/07/2023] [Accepted: 01/23/2024] [Indexed: 02/09/2024] Open
Abstract
PURPOSE The aim of the present study, conducted by a working group of the Italian Association of Medical Physics (AIFM), was to define typical z-resolution values for different digital breast tomosynthesis (DBT) models to be used as a reference for quality control (QC). Currently, there are no typical values published in internationally agreed QC protocols. METHODS To characterize the z-resolution of the DBT models, the full width at half maximum (FWHM) of the artifact spread function (ASF), a technical parameter that quantifies the signal intensity of a detail along reconstructed planes, was analyzed. Five different commercial phantoms, CIRS Model 011, CIRS Model 015, Modular DBT phantom, Pixmam 3-D, and Tomophan, were evaluated on reconstructed DBT images and 82 DBT systems (6 vendors, 9 models) in use at 39 centers in Italy were involved. RESULTS The ASF was found to be dependent on the detail size, the DBT angular acquisition range, the reconstruction algorithm and applied image processing. In particular, a progressively greater signal spread was observed as the detail size increased and the acquisition angle decreased. However, a clear correlation between signal spread and angular range width was not observed due to the different signal reconstruction and image processing strategies implemented in the algorithms developed by the vendors studied. CONCLUSIONS The analysis led to the identification of typical z-resolution values for different DBT model-phantom configurations that could be used as a reference during a QC program.
Collapse
Affiliation(s)
- S Dalmonte
- Medical Physics Specialization School, University of Bologna, Bologna, Italy; Medical Physics Unit, AUSL Romagna, Ravenna, Italy.
| | - P Golinelli
- Medical Physics Unit, Azienda USL Modena, Modena, Italy
| | | | - S Strocchi
- Medical Physics Unit, ASST dei Sette Laghi, Varese, Italy
| | - V Rossetti
- Medical Physics Unit, Città della salute e della scienza, Torino, Italy
| | - L Berta
- Medical Physics Unit, Città della salute e della scienza, Torino, Italy
| | - M Porzio
- Medical Physics Unit, ASL CN1, Cuneo, Italy
| | - L Angelini
- Medical Physics Unit, AUSL Romagna, Ravenna, Italy
| | - N Paruccini
- Medical Physics Unit, ASST Monza, Monza, Italy
| | - R Villa
- Medical Physics Unit, ASST Monza, Monza, Italy
| | - M Bertolini
- Medical Physics Unit, Azienda AUSL - IRCCS di Reggio Emilia, Reggio Emilia, Italy
| | - S Delle Canne
- Medical Physics Unit, Fatebenefratelli Isola Tiberina-Gemelli Isola, Roma, Italy
| | - M Cavallari
- Medical Physics Unit, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy
| | - L D'Ercole
- Medical Physics Unit, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy
| | - G Guerra
- Medical Physics Unit, Studio Associato Fisici Sanitari, Lugo, Italy
| | - R Rosasco
- Medical Physics Unit, ASL3 Sistema Sanitario Regione Liguria, Genova, Italy
| | - B Cannillo
- Medical Physics Unit, AOU Maggiore della Carità, Novara, Italy
| | - A D'Alessio
- Medical Physics Unit, AOU Maggiore della Carità, Novara, Italy
| | - E Di Nicola
- Medical Physics Unit, ASUR Marche Area Vasta3, Macerata, Italy
| | - D Origgi
- Medical Physics Unit, IEO, European Institute of Oncology IRCCS, Milan, Italy
| | - P De Marco
- Medical Physics Unit, IEO, European Institute of Oncology IRCCS, Milan, Italy
| | - A Maldera
- Medical Physics Unit, P.O. Dimiccoli - ASL BT, Barletta, Italy
| | - C Scabbio
- Medical Physics Unit, ASST Santi Paolo e Carlo - Presidio San Paolo, Milano, Italy
| | - F Rottoli
- Medical Physics Unit, ASST Santi Paolo e Carlo - Presidio San Paolo, Milano, Italy
| | - R Castriconi
- Medical Physics Unit, IRCCS Ospedale San Raffaele - Gruppo San Donato, Milano, Italy
| | - E Lorenzini
- Medical Physics Unit, Ospedale Civico di Carrara, Carrara, Italy
| | - G Pasquali
- Medical Physics Unit, ASST Bergamo Ovest, Treviglio, Italy
| | - F Pietrobon
- Medical Physics Unit, Ospedale di Belluno, Belluno, Italy
| | - P Bregant
- Medical Physics Unit, Ospedale Cattinara, Trieste, Italy
| | - G Giovannini
- Medical Physics Unit, ASL2 Ospedale Santa Corona, Pietra Ligure, Italy
| | - V Favuzza
- Medical Physics Unit, USL Toscana Centro, Empoli, Italy
| | - A Bruschi
- Medical Physics Unit, USL Toscana Centro, Empoli, Italy
| | - D D'Urso
- Medical Physics Unit, ULSS 2 Marca Trevigiana, Treviso, Italy
| | - D Maestri
- Medical Physics Unit, ULSS 2 Marca Trevigiana, Treviso, Italy
| | | | - A Fracassi
- Medical Physics Unit, ASL Pescara, Pescara, Italy
| | - L Boschiroli
- Medical Physics Unit, ASST Nord Milano, Milano, Italy
| | - M Quattrocchi
- Medical Physics Unit, Azienda Toscana Nord Ovest, Lucca, Italy
| | - M A Gilio
- Medical Physics Unit, Azienda Toscana Nord Ovest, Lucca, Italy
| | - E Roberto
- Medical Physics Unit, ASL CN2 Cuneo, Italy
| | - L Altabella
- Medical Physics Unit, AOUI VR, Verona, Italy
| | - G Califano
- Medical Physics Unit, AOR San Carlo Potenza, Potenza, Italy
| | - M C Cimmino
- Medical Physics Unit, USL Toscana sud est, Siena, Italy
| | - E Bortoli
- Medical Physics Unit, USL Toscana sud est, Grosseto, Italy
| | - E Deiana
- Medical Physics Unit, ASL Cagliari, Cagliari, Italy
| | - L Pagan
- Medical Physics Unit, Azienda USL Bologna, Bologna, Italy
| | - P Berardi
- Medical Physics Unit, Azienda USL Bologna, Bologna, Italy
| | - V Ardu
- Medical Physics Unit, Fondazione IRCCS Ca' Granda, Milano, Italy
| | - R Azzeroni
- Medical Physics Unit, Fondazione IRCCS Ca' Granda, Milano, Italy
| | - M Campoleoni
- Medical Physics Unit, Fondazione IRCCS Ca' Granda, Milano, Italy
| | - V Ravaglia
- Medical Physics Unit, AUSL Romagna, Ravenna, Italy
| |
Collapse
|
4
|
Burgel PR, Sermet-Gaudelus I, Girodon E, Kanaan R, Le Bihan J, Remus N, Ravoninjatovo B, Grenet D, Porzio M, Houdouin V, Le Clainche-Viala L, Durieu I, Nove-Josserand R, Languepin J, Coltey B, Guillaumot A, Audousset C, Chiron R, Weiss L, Fajac I, Da Silva J, Martin C. Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rare CFTR variants: a viewpoint. Eur Respir J 2024; 63:2301959. [PMID: 38242629 DOI: 10.1183/13993003.01959-2023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2023] [Accepted: 12/19/2023] [Indexed: 01/21/2024]
Affiliation(s)
- Pierre-Régis Burgel
- Université Paris-Cité, Institut Cochin, Inserm U1016, Paris, France
- Respiratory Medicine and Cystic Fibrosis National Reference Center, Cochin Hospital, Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France
- ERN-Lung CF network, Frankfurt, Germany
| | - Isabelle Sermet-Gaudelus
- ERN-Lung CF network, Frankfurt, Germany
- Centre de de Référence Maladies Rares, Mucoviscidose et affections liées à CFTR, Pneumologie Pédiatrique et Allergologie, Hôpital Necker Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France
- Université Paris-Cité, Institut Necker Enfants Malades, INSERM U1151, Paris, France
| | - Emmanuelle Girodon
- APHP.Centre-Université de Paris Cité, Service de Médecine Génomique des Maladies de Système et d'Organe, Hôpital Cochin, Paris, France
| | - Reem Kanaan
- Respiratory Medicine and Cystic Fibrosis National Reference Center, Cochin Hospital, Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France
- ERN-Lung CF network, Frankfurt, Germany
| | - Jean Le Bihan
- CF Centre, Centre Perharidy, Service de Soins de Suite Nutritionnelle et Respiratoire, Roscoff, France
| | - Natascha Remus
- Centre Hospitalier Intercommunal de Créteil, Service de Pédiatrie Générale, Créteil, France
| | - Bruno Ravoninjatovo
- Department of Respiratory Diseases, Reims University Hospital, Reims, France
| | - Dominique Grenet
- CRCM - Centre de Transplantation Pulmonaire, Service de pneumologie, hôpital Foch, Suresnes, France
| | - Michele Porzio
- Department of Respiratory Medicine and Cystic Fibrosis Center, Federation of Translational Medicine of Strasbourg (FMTS), University Hospitals, Strasbourg, France
| | - Véronique Houdouin
- Université Paris-Cité, Institut Cochin, Inserm U1016, Paris, France
- Hôpital Robert Debré, Paris, France
| | | | - Isabelle Durieu
- ERN-Lung CF network, Frankfurt, Germany
- Centre de référence Adulte de la Mucoviscidose, Service de médecine interne, Hospices civils de Lyon, Pierre Bénite, France
- Université de Lyon, Research on Healthcare Performance (RESHAPE), INSERM U1290, Lyon, France
| | - Raphaele Nove-Josserand
- ERN-Lung CF network, Frankfurt, Germany
- Centre de référence Adulte de la Mucoviscidose, Service de médecine interne, Hospices civils de Lyon, Pierre Bénite, France
| | | | - Bérangère Coltey
- Department of Respiratory Medicine and Lung Transplantation, Aix Marseille Univ, APHM, Hôpital Nord, Marseille, France
| | - Anne Guillaumot
- CRCM Adultes, Département de Pneumologie, CHRU de Nancy, Université de Lorraine, F-5400 Nancy, France
| | - Camille Audousset
- Centre de Mucoviscidose, Service de Pneumologie et Immuno-allergologie, Hôpital Calmette, Centre Hospitalier Universitaire de Lille, Université de Lille, Lille, France
| | - Raphaël Chiron
- Cystic Fibrosis Center, Hôpital Arnaud de Villeneuve, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
| | | | - Isabelle Fajac
- Université Paris-Cité, Institut Cochin, Inserm U1016, Paris, France
- Respiratory Medicine and Cystic Fibrosis National Reference Center, Cochin Hospital, Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France
- ERN-Lung CF network, Frankfurt, Germany
| | - Jennifer Da Silva
- Respiratory Medicine and Cystic Fibrosis National Reference Center, Cochin Hospital, Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France
- ERN-Lung CF network, Frankfurt, Germany
| | - Clémence Martin
- Université Paris-Cité, Institut Cochin, Inserm U1016, Paris, France
- Respiratory Medicine and Cystic Fibrosis National Reference Center, Cochin Hospital, Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France
- ERN-Lung CF network, Frankfurt, Germany
| |
Collapse
|
5
|
Dreano E, Burgel PR, Hatton A, Bouazza N, Chevalier B, Macey J, Leroy S, Durieu I, Weiss L, Grenet D, Stremler N, Ohlmann C, Reix P, Porzio M, Roux Claude P, Rémus N, Douvry B, Montcouquiol S, Cosson L, Mankikian J, Languepin J, Houdouin V, Le Clainche L, Guillaumot A, Pouradier D, Tissot A, Priou P, Mély L, Chedevergne F, Lebourgeois M, Lebihan J, Martin C, Zavala F, Da Silva J, Lemonnier L, Kelly-Aubert M, Golec A, Foucaud P, Marguet C, Edelman A, Hinzpeter A, de Carli P, Girodon E, Sermet-Gaudelus I, Pranke I. Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescription. Eur Respir J 2023; 62:2300110. [PMID: 37696564 DOI: 10.1183/13993003.00110-2023] [Citation(s) in RCA: 11] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2023] [Accepted: 08/16/2023] [Indexed: 09/13/2023]
Abstract
BACKGROUND Around 20% of people with cystic fibrosis (pwCF) do not have access to the triple combination elexacaftor/tezacaftor/ivacaftor (ETI) in Europe because they do not carry the F508del allele on the CF transmembrane conductance regulator (CFTR) gene. Considering that pwCF carrying rare variants may benefit from ETI, including variants already validated by the US Food and Drug Administration (FDA), a compassionate use programme was launched in France. PwCF were invited to undergo a nasal brushing to investigate whether the pharmacological rescue of CFTR activity by ETI in human nasal epithelial cell (HNEC) cultures was predictive of the clinical response. METHODS CFTR activity correction was studied by short-circuit current in HNEC cultures at basal state (dimethyl sulfoxide (DMSO)) and after ETI incubation and expressed as percentage of normal (wild-type (WT)) CFTR activity after sequential addition of forskolin and Inh-172 (ΔI ETI/DMSO%WT). RESULTS 11 pwCF carried variants eligible for ETI according to the FDA label and 28 carried variants not listed by the FDA. ETI significantly increased CFTR activity of FDA-approved CFTR variants (I601F, G85E, S492F, M1101K, R347P, R74W;V201M;D1270N and H1085R). We point out ETI correction of non-FDA-approved variants, including N1303K, R334W, R1066C, Q552P and terminal splicing variants (4374+1G>A and 4096-3C>G). ΔI ETI/DMSO%WT was significantly correlated to change in percentage predicted forced expiratory volume in 1 s and sweat chloride concentration (p<0.0001 for both). G85E, R74W;V201M;D1270N, Q552P and M1101K were rescued more efficiently by other CFTR modulator combinations than ETI. CONCLUSIONS Primary nasal epithelial cells hold promise for expanding the prescription of CFTR modulators in pwCF carrying rare mutants. Additional variants should be discussed for ETI indication.
Collapse
Affiliation(s)
- Elise Dreano
- INSERM, CNRS, Institut Necker Enfants Malades, Paris, France
- Université Paris-Cité, Paris, France
| | - Pierre Régis Burgel
- Université Paris-Cité, Paris, France
- Respiratory Medicine and Cystic Fibrosis National Reference Center, Cochin Hospital, AP-HP, Paris, France
- INSERM U1016, Institut Cochin, Paris, France
- ERN-LUNG CF Network, Frankfurt, Germany
| | - Aurelie Hatton
- INSERM, CNRS, Institut Necker Enfants Malades, Paris, France
- Université Paris-Cité, Paris, France
| | - Naim Bouazza
- Université Paris-Cité, Paris, France
- Unité de Recherche Clinique, Hôpital Necker Enfants Malades, AP-HP, Paris, France
| | - Benoit Chevalier
- INSERM, CNRS, Institut Necker Enfants Malades, Paris, France
- Université Paris-Cité, Paris, France
| | - Julie Macey
- Centre de Ressources et de Compétence de la Mucoviscidose, CHU Pellegrin, Bordeaux, France
| | - Sylvie Leroy
- Centre de Ressources et de Compétence de la Mucoviscidose, CHU, Nice, France
| | - Isabelle Durieu
- Centre de Référence Adulte de la Mucoviscidose, Hospices Civils de Lyon, Université de Lyon, Équipe d'Accueil Health Services and Performance Research (HESPER) 7425, Lyon, France
| | - Laurence Weiss
- Centre de Ressources et de Compétence de la Mucoviscidose Pédiatrique, CHU, Strasbourg, France
| | - Dominique Grenet
- Centre de Ressources et de Compétence de la Mucoviscidose, Hôpital Foch, Suresnes, France
| | - Nathalie Stremler
- Centre de Ressources et de Compétence de la Mucoviscidose, Hôpital de la Timone, Marseille, France
| | - Camille Ohlmann
- Centre de Ressources et de Compétence de la Mucoviscidose Pédiatrique, Hospices Civils de Lyon, Bron, France
| | - Philippe Reix
- Centre de Ressources et de Compétence de la Mucoviscidose Pédiatrique, Hospices Civils de Lyon, Bron, France
| | - Michele Porzio
- Centre de Ressources et de Compétence de la Mucoviscidose Adulte, CHU, Strasbourg, France
| | - Pauline Roux Claude
- Centre de Ressources et de Compétence de la Mucoviscidose Adulte, CHU, Besancon, France
| | - Natacha Rémus
- Centre de Ressources et de Compétence de la Mucoviscidose Mixte, CHIC, Créteil, France
| | - Benoit Douvry
- Centre de Ressources et de Compétence de la Mucoviscidose Mixte, CHIC, Créteil, France
| | - Sylvie Montcouquiol
- Centre de Ressources et de Compétence de la Mucoviscidose Adulte, CHU, Clermont Ferrand, France
| | - Laure Cosson
- Centre de Ressources et de Compétence de la Mucoviscidose Pédiatrique, CHU, Tours, France
| | - Julie Mankikian
- Centre de Ressources et de Compétence de la Mucoviscidose Adulte, CHU, Tours, France
| | - Jeanne Languepin
- Centre de Ressources et de Compétence de la Mucoviscidose Mixte, CHU, Limoges, France
| | - Veronique Houdouin
- Centre de Ressources et de Compétence de la Mucoviscidose Pédiatrique, Hôpital Robert Debré, Paris, France
| | - Laurence Le Clainche
- Centre de Ressources et de Compétence de la Mucoviscidose Pédiatrique, Hôpital Robert Debré, Paris, France
| | - Anne Guillaumot
- Centre de Ressources et de Compétence de la Mucoviscidose Adulte, CHU, Nancy, France
| | - Delphine Pouradier
- Centre de Ressources et de Compétence de la Mucoviscidose Pédiatrique, Hôpital Mignot, Le Chesnay, France
| | - Adrien Tissot
- Centre de Ressources et de Compétence de la Mucoviscidose Adulte, CHU, Nantes, France
| | - Pascaline Priou
- Centre de Ressources et de Compétence de la Mucoviscidose Adulte, CHU, Angers, France
| | - Laurent Mély
- Centre de Ressources et de Compétence de la Mucoviscidose, Hôpital René Sabran, Hospices Civils de Lyon, Giens, France
| | - Frederique Chedevergne
- Cystic Fibrosis National Pediatric Reference Center, Pneumo-Allergologie Pédiatrique, Hôpital Necker Enfants Malades, AP-HP, Paris, France
| | - Muriel Lebourgeois
- Cystic Fibrosis National Pediatric Reference Center, Pneumo-Allergologie Pédiatrique, Hôpital Necker Enfants Malades, AP-HP, Paris, France
| | - Jean Lebihan
- Centre de Ressources et de Compétence de la Mucoviscidose Adulte, Centre de Perharidy, Roscoff, France
| | - Clémence Martin
- Université Paris-Cité, Paris, France
- Respiratory Medicine and Cystic Fibrosis National Reference Center, Cochin Hospital, AP-HP, Paris, France
| | - Flora Zavala
- INSERM, CNRS, Institut Necker Enfants Malades, Paris, France
- Université Paris-Cité, Paris, France
| | - Jennifer Da Silva
- Respiratory Medicine and Cystic Fibrosis National Reference Center, Cochin Hospital, AP-HP, Paris, France
| | | | - Mairead Kelly-Aubert
- INSERM, CNRS, Institut Necker Enfants Malades, Paris, France
- Université Paris-Cité, Paris, France
| | - Anita Golec
- INSERM, CNRS, Institut Necker Enfants Malades, Paris, France
- Université Paris-Cité, Paris, France
| | | | - Christophe Marguet
- Centre de Ressources et de Compétence de la Mucoviscidose Pédiatrique, CHU, Rouen, France
| | - Aleksander Edelman
- INSERM, CNRS, Institut Necker Enfants Malades, Paris, France
- Université Paris-Cité, Paris, France
| | - Alexandre Hinzpeter
- INSERM, CNRS, Institut Necker Enfants Malades, Paris, France
- Université Paris-Cité, Paris, France
| | | | - Emmanuelle Girodon
- INSERM, CNRS, Institut Necker Enfants Malades, Paris, France
- Université Paris-Cité, Paris, France
- Service de Médecine Génomique des Maladies de Système et d'Organe, Hôpital Cochin, Paris, France
- These three authors contributed equally to this work as co-last authors
| | - Isabelle Sermet-Gaudelus
- INSERM, CNRS, Institut Necker Enfants Malades, Paris, France
- Université Paris-Cité, Paris, France
- ERN-LUNG CF Network, Frankfurt, Germany
- Centre de Ressources et de Compétence de la Mucoviscidose Pédiatrique, Hôpital Mignot, Le Chesnay, France
- These three authors contributed equally to this work as co-last authors
| | - Iwona Pranke
- INSERM, CNRS, Institut Necker Enfants Malades, Paris, France
- Université Paris-Cité, Paris, France
- These three authors contributed equally to this work as co-last authors
| |
Collapse
|
6
|
Guibert N, Mazières J, Moreno B, Dutau H, Plat G, Héluain V, Kessler R, Porzio M. 'Double-bifurcated' stent: when 3D is not an option. Thorax 2023; 78:735-736. [PMID: 36990692 DOI: 10.1136/thorax-2022-219954] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2022] [Accepted: 03/11/2023] [Indexed: 03/31/2023]
Affiliation(s)
- Nicolas Guibert
- Pulmonology, University Hospital Centre Toulouse, Toulouse, France
| | - Julien Mazières
- Thoracic Oncology, CHU Toulouse, Hôpital Larrey, Toulouse, France
| | | | - Hervé Dutau
- Department of Thoracic Oncology, Pleural Diseases and Interventional Pulmonology, Assistance Publique-Hôpitaux de Marseille (AP-HM), Hopital Nord, Marseille, France
| | - Gavin Plat
- Pulmonology, CHU Toulouse, hopital Larrey, Toulouse, France
| | | | | | | |
Collapse
|
7
|
Burgel PR, Sermet-Gaudelus I, Durieu I, Kanaan R, Macey J, Grenet D, Porzio M, Coolen-Allou N, Chiron R, Marguet C, Douvry B, Dufeu N, Danner-Boucher I, Foucaud P, Lemonnier L, Girodon E, Da Silva J, Martin C. The French Compassionate Program of elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant. Eur Respir J 2023:2202437. [PMID: 36796836 DOI: 10.1183/13993003.02437-2022] [Citation(s) in RCA: 24] [Impact Index Per Article: 24.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2022] [Accepted: 02/08/2023] [Indexed: 02/18/2023]
Abstract
BACKGROUND The European Medicines Agency has approved the cystic fibrosis transmembrane conductance regulator (CFTR) modulator combination elexacaftor-tezacaftor-ivacaftor (ETI) for people with cystic fibrosis (pwCF) carrying at least one F508del variant. The United States Food and Drug Administration (FDA) also approved ETI for pwCF carrying one of 177 rare variants. METHODS An observational study was conducted to evaluate the effectiveness of ETI in pwCF with advanced lung disease that were not eligible to ETI in Europe. All patients with no F508del variant and advanced lung disease (defined as having a percent predicted forced expiratory volume (ppFEV1)<40 and/or being under evaluation for lung transplantation) and enrolled in the French Compassionate Program initiated ETI at recommended doses. Effectiveness was evaluated by a centralized adjudication committee at 4-6 weeks in terms of clinical manifestations, sweat chloride concentration and ppFEV1. RESULTS Among the first 84 pwCF included in the program, ETI was effective in 45 (54%) and 39 (46%) were considered to be non-responders. Among the responders 22/45 (49%) carried a CFTR variant that is not currently approved by FDA for ETI eligibility. Important clinical benefits, including suspending the indication for lung transplantation, a significant decrease in sweat chloride concentration by a median [IQR] -30 [-14;-43]mmol·l-1 (n=42; p<0.0001) and an improvement in ppFEV1 by+10.0 [6.0; 20.5] (n=44, p<0.0001), were observed in those for whom treatment was effective. CONCLUSION Clinical benefits were observed in a large subset of pwCF with advanced lung disease and CFTR variants not currently approved for ETI.
Collapse
Affiliation(s)
- Pierre-Régis Burgel
- Université Paris-Cité, Institut Cochin, Inserm U1016, Paris, France
- Respiratory Medicine and Cystic Fibrosis National Reference Center; Cochin Hospital; Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France
- ERN-Lung CF network, Frankfurt, Germany
| | - Isabelle Sermet-Gaudelus
- ERN-Lung CF network, Frankfurt, Germany
- Centre de de Référence Maladies Rares, Mucoviscidose et affections liées à CFTR, Pneumologie Pédiatrique et Allergologie, Hôpital Necker Enfants Malades, Assistance Publique-Hôpitaux de Paris, Paris, France
- Université Paris-Cité, Institut Necker Enfants Malades, INSERM U1151, Paris, France
| | - Isabelle Durieu
- ERN-Lung CF network, Frankfurt, Germany
- Centre de référence Adulte de la Mucoviscidose, Service de médecine interne, Hospices civils de Lyon, Pierre Bénite, France
- Université de Lyon, Équipe d'Accueil Health Services and Performance Research (HESPER) 7425, Lyon, France
| | - Reem Kanaan
- Respiratory Medicine and Cystic Fibrosis National Reference Center; Cochin Hospital; Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France
- ERN-Lung CF network, Frankfurt, Germany
| | - Julie Macey
- Respiratory Medicine and Cystic Fibrosis Center, CHU de Bordeaux, Bordeaux, France
| | - Dominique Grenet
- CRCM - Centre de Transplantation Pulmonaire. Service de pneumologie, hôpital Foch, Suresnes, France
| | - Michele Porzio
- Department of Respiratory Medicine and Cystic Fibrosis Center, Federation of Translational Medicine of Strasbourg (FMTS), University Hospitals, Strasbourg, France
| | | | - Raphael Chiron
- Cystic Fibrosis Center, Hôpital Arnaud de Villeneuve, Centre Hospitalier Universitaire de Montpellier, Montpellier, France
| | - Christophe Marguet
- Pediatric Respiratory Disease and Cystic Fibrosis Center, Hospital, UNIROUEN, Inserm EA 2656, Rouen University Hospital, Normandie Univ, Rouen, France
| | - Benoit Douvry
- Service de Pneumologie, Centre Hospitalier Intercommunal, FHU SENEC, Créteil, France
| | - Nadine Dufeu
- Department of Respiratory Medicine and Lung Transplantation, Aix Marseille Univ, APHM, Hôpital Nord, Marseille, France
| | | | | | | | - Emmanuelle Girodon
- APHP.Centre-Université de Paris Cité, Service de Médecine Génomique des Maladies de Système et d'Organe, Hôpital Cochin, Paris, France
| | - Jennifer Da Silva
- Respiratory Medicine and Cystic Fibrosis National Reference Center; Cochin Hospital; Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France
- ERN-Lung CF network, Frankfurt, Germany
| | - Clémence Martin
- Université Paris-Cité, Institut Cochin, Inserm U1016, Paris, France
- Respiratory Medicine and Cystic Fibrosis National Reference Center; Cochin Hospital; Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France
- ERN-Lung CF network, Frankfurt, Germany
| |
Collapse
|
8
|
Riou M, Canuet M, Ghigna MR, Eyries M, Chenard MP, Porzio M, Olland A, Humbert M, Kessler R, Montani D. First histological description of pulmonary and vascular abnormalities of pulmonary hypertension associated with KDR pathogenic variant. Eur Respir J 2022; 60:13993003.01197-2022. [PMID: 36180087 DOI: 10.1183/13993003.01197-2022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2022] [Accepted: 09/16/2022] [Indexed: 11/05/2022]
Affiliation(s)
- Marianne Riou
- Department of Physiology and Functional Exploration, Nouvel Hôpital Civil, Les Hôpitaux universitaires de Strasbourg, France.,Chest diseases department, Nouvel Hôpital Civil, Les Hôpitaux universitaires de Strasbourg, France
| | - Matthieu Canuet
- Chest diseases department, Nouvel Hôpital Civil, Les Hôpitaux universitaires de Strasbourg, France
| | - Maria-Rosa Ghigna
- Department of pathology, Hôpital Marie Lannelongue, Le Plessis Robinson, France
| | - Mélanie Eyries
- Genetics Department, Hôpital Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, France, and UMR_S 1166 Sorbonne Université, France
| | - Marie Pierrette Chenard
- Department of pathology, Hôpital de Hautepierre, Les Hôpitaux universitaires de Strasbourg, France
| | - Michele Porzio
- Chest diseases department, Nouvel Hôpital Civil, Les Hôpitaux universitaires de Strasbourg, France
| | - Anne Olland
- Department of Thoracic Surgery, Nouvel Hôpital Civil, Les Hôpitaux universitaires de Strasbourg, France
| | - Marc Humbert
- Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.,Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France
| | - Romain Kessler
- Chest diseases department, Nouvel Hôpital Civil, Les Hôpitaux universitaires de Strasbourg, France
| | - David Montani
- Assistance Publique - Hôpitaux de Paris (AP-HP), Department of Respiratory and Intensive Care Medicine, Pulmonary Hypertension National Referral Center, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.,Université Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999 "Pulmonary Hypertension: Pathophysiology and Novel Therapies", Hôpital Marie Lannelongue, Le Plessis-Robinson, France
| |
Collapse
|
9
|
Rakotoarisoa L, Weiss L, Lefebvre F, Porzio M, Ravoninjatovo B, Abely M, Boucher ID, Dubois S, Troussier F, Gilles R, Prevotat A, Kessler L. Comparison of Continuous Glucose Monitoring in Cystic Fibrosis Patients With or Without Pancreatic Exocrine Insufficiency. Horm Metab Res 2022; 54:407-412. [PMID: 35272389 DOI: 10.1055/a-1794-5496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
This study aimed to compare continuous glucose monitoring (CGM) in cystic fibrosis (CF) according to pancreatic exocrine status.CGM and oral glucose tolerance testing (OGTT) were realized annually over five years in people with CF (pwCF) aged≥10 years without cystic fibrosis-related diabetes (CFRD). CGM parameters in patients with normal glucose tolerance (NGT), impaired glucose tolerance (IGT), and newly diagnosed CFRD were compared according to presence of pancreatic sufficiency (PS) or insufficiency (PI).Overall, 547 OGTTs and 501 CGMs were performed in 147 CF patients, comprising 122 PI and 25 PS. In PS patients, 84% displayed NGT, 12% IGT, and 4% CFRD vs. 58%, 32%, and 10% (p=0.05) in PI. Among participants displaying normal OGTT, time in glucose range (70-140 mg/dl) was significantly increased, 97% (93, 99) vs. 92% (85, 96), p<0.001, and time above glucose range > 140 mg/dl significantly decreased, 1% (0, 2) % vs. 6% (2, 13), in patients with PS compared to those with PI. No significant differences were highlighted in patients with IGT.CGM revealed significant different glucose tolerance abnormalities in PI versus PS, which were undetected by standard 2-hour OGTT glucose.
Collapse
Affiliation(s)
- Luc Rakotoarisoa
- Department of Diabetology, University Hospital Strasbourg, Strasbourg, France
- Inserm UMR 1260, Regenerative Nanomedicine, University of Strasbourg, Strasbourg, France
| | - Laurence Weiss
- CRCM, University Hospital Strasbourg, Strasbourg, France
| | | | - Michele Porzio
- CRCM, University Hospital Strasbourg, Strasbourg, France
| | | | - Michel Abely
- CRCM, University Hospital Centre Reims, Reims, France
| | | | - Séverine Dubois
- Diabetology, University Hospital Centre Angers, Angers, France
| | | | | | - Anne Prevotat
- Allergology, Lille University Hospital Center, Lille, France
| | - Laurence Kessler
- Department of Diabetology, University Hospital Strasbourg, Strasbourg, France
- Inserm UMR 1260, Regenerative Nanomedicine, University of Strasbourg, Strasbourg, France
| |
Collapse
|
10
|
Porzio M, Rembado D, Gentile L. Photon counting as a valuable technology for breast screening: low glandular doses and good image quality. Phys Med 2021. [DOI: 10.1016/s1120-1797(22)00485-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
11
|
Matar M, Kessler R, Olland A, Falcoz P, Desprez P, Roche A, Collange O, Chenard MP, Renaud-Picard B, Porzio M. End-Stage Respiratory Failure Secondary to Bronchiolitis Obliterans Syndrome Induced by Toxic Epidermal Necrosis, Also Known as Lyell Syndrome: A Case Report. Transplant Proc 2021; 53:1371-1374. [PMID: 33896544 DOI: 10.1016/j.transproceed.2021.03.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2021] [Accepted: 03/17/2021] [Indexed: 11/17/2022]
Abstract
BACKGROUND Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but serious dermatologic diseases. They can be associated with systemic manifestations such as bronchiolitis obliterans syndrome (BOS). SJS/TEN-induced BOS is associated with a poor prognosis, and no guidelines exist regarding its management. Several case reports have described the association between SJS/TEN and BOS, with few patients undergoing lung transplantation as a last resort therapy. Unfortunately, in the published reports, none of the transplanted patients were observed for a long period of time after the transplantation; therefore, the long-term mortality as well as the risk of recurrence of BOS could not be inferred from these reports. CASE REPORT We present the case of a young patient diagnosed with SJS complicated by BOS and end-stage respiratory failure refractory to corticosteroid therapy. She underwent bilateral lung transplantation with an outstanding outcome at 5-year follow-up. CONCLUSION SJS/TEN-induced BOS might have a favorable evolution and long-term outcomes following lung transplantation. However, prospective studies are needed to confirm this finding.
Collapse
Affiliation(s)
- Maroun Matar
- Strasbourg Lung Transplant Program, University Hospital, Strasbourg, France.
| | - Romain Kessler
- Strasbourg Lung Transplant Program, University Hospital, Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg, Strasbourg, France; Institut National de la Santé et de la Recherche Médicale-Université de Strasbourg, Unité Mixte de Recherche 1260 Regenerative Ranomedecine, Strasbourg, France
| | - Anne Olland
- Strasbourg Lung Transplant Program, University Hospital, Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg, Strasbourg, France; Institut National de la Santé et de la Recherche Médicale-Université de Strasbourg, Unité Mixte de Recherche 1260 Regenerative Ranomedecine, Strasbourg, France
| | - Pierre Falcoz
- Strasbourg Lung Transplant Program, University Hospital, Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg, Strasbourg, France; Institut National de la Santé et de la Recherche Médicale-Université de Strasbourg, Unité Mixte de Recherche 1260 Regenerative Ranomedecine, Strasbourg, France
| | - Philippe Desprez
- Pediatric Intensive Care Unit, University Hospital, Strasbourg, France
| | - Anne Roche
- Surgical Intensive Care Unit, University Hospital, Strasbourg, France
| | - Olivier Collange
- Fédération de Médecine Translationnelle de Strasbourg, Strasbourg, France; Surgical Intensive Care Unit, University Hospital, Strasbourg, France
| | | | - Benjamin Renaud-Picard
- Strasbourg Lung Transplant Program, University Hospital, Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg, Strasbourg, France; Institut National de la Santé et de la Recherche Médicale-Université de Strasbourg, Unité Mixte de Recherche 1260 Regenerative Ranomedecine, Strasbourg, France
| | - Michele Porzio
- Strasbourg Lung Transplant Program, University Hospital, Strasbourg, France; Fédération de Médecine Translationnelle de Strasbourg, Strasbourg, France
| |
Collapse
|
12
|
Burgel PR, Durieu I, Chiron R, Mely L, Prevotat A, Murris-Espin M, Porzio M, Abely M, Reix P, Marguet C, Macey J, Sermet-Gaudelus I, Corvol H, Bui S, Biouhee T, Hubert D, Munck A, Lemonnier L, Dehillotte C, Silva JD, Paillasseur JL, Martin C. Clinical response to lumacaftor-ivacaftor in patients with cystic fibrosis according to baseline lung function. J Cyst Fibros 2021; 20:220-227. [DOI: 10.1016/j.jcf.2020.06.012] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2020] [Revised: 06/04/2020] [Accepted: 06/04/2020] [Indexed: 01/08/2023]
|
13
|
Renaud-Picard B, Gallais F, Riou M, Chatron E, Degot T, Freudenberger S, Porzio M, Schuller A, Stauder J, Hirschi S, Kessler R. The social and clinical impact of the COVID-19 epidemic on the Strasbourg lung transplant cohort: A single-center retrospective cohort study. Clin Transplant 2020; 34:e14119. [PMID: 33048391 PMCID: PMC7646014 DOI: 10.1111/ctr.14119] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2020] [Revised: 09/12/2020] [Accepted: 09/30/2020] [Indexed: 12/11/2022]
Abstract
The clinical and social impacts of the COVID-19 epidemic on lung transplant (LTx) recipients remain poorly known. We aimed to evaluate its social, clinical, and behavioral consequences on the LTx patients followed in Strasbourg university hospital. A questionnaire was used to collect details concerning patients' lifestyles, their protection methods used to avoid COVID-19 contamination, and clinical infection-related information for March 2020. A specific score was created to quantify patients' contacts and the associated risk of infectious contagion. Data were collected from 322 patients (91.2%). A majority reported a higher application than usual of social distancing and barrier measures. 43.8% described infectious-related symptoms and 15.8% needed an anti-infective treatment. There was no difference in symptom onset according to age, native lung disease, diabetes, or obesity. Nineteen patients were tested for COVID-19, and four were diagnosed positive, all with a favorable outcome. The infection risk contact score was higher for symptomatic patients (p: 0.007), those needing extra-medical appointments (p < .001), and those receiving anti-infective treatments (p = .02). LTx patients reported a careful lifestyle and did not seem at higher risk for COVID-19. Our score showed encouraging preliminary results and could become a useful tool for the usual infection-related follow-up of the LTx patients.
Collapse
Affiliation(s)
- Benjamin Renaud-Picard
- Respiratory Medicine and Strasbourg Lung Transplant Program, Hôpitaux universitaires de Strasbourg, Strasbourg, France.,Faculty of Medicine, Federation of Translational Medicine (FMTS), Strasbourg, France
| | - Floriane Gallais
- Laboratory of Virology, Hôpitaux universitaires de Strasbourg, Strasbourg, France
| | - Marianne Riou
- Respiratory Medicine and Strasbourg Lung Transplant Program, Hôpitaux universitaires de Strasbourg, Strasbourg, France.,Faculty of Medicine, Federation of Translational Medicine (FMTS), Strasbourg, France
| | - Eva Chatron
- Respiratory Medicine and Strasbourg Lung Transplant Program, Hôpitaux universitaires de Strasbourg, Strasbourg, France.,Faculty of Medicine, Federation of Translational Medicine (FMTS), Strasbourg, France
| | - Tristan Degot
- Respiratory Medicine and Strasbourg Lung Transplant Program, Hôpitaux universitaires de Strasbourg, Strasbourg, France
| | - Sophie Freudenberger
- Respiratory Medicine and Strasbourg Lung Transplant Program, Hôpitaux universitaires de Strasbourg, Strasbourg, France
| | - Michele Porzio
- Respiratory Medicine and Strasbourg Lung Transplant Program, Hôpitaux universitaires de Strasbourg, Strasbourg, France.,Faculty of Medicine, Federation of Translational Medicine (FMTS), Strasbourg, France
| | - Armelle Schuller
- Respiratory Medicine and Strasbourg Lung Transplant Program, Hôpitaux universitaires de Strasbourg, Strasbourg, France
| | - Julien Stauder
- Respiratory Medicine and Strasbourg Lung Transplant Program, Hôpitaux universitaires de Strasbourg, Strasbourg, France
| | - Sandrine Hirschi
- Respiratory Medicine and Strasbourg Lung Transplant Program, Hôpitaux universitaires de Strasbourg, Strasbourg, France
| | - Romain Kessler
- Respiratory Medicine and Strasbourg Lung Transplant Program, Hôpitaux universitaires de Strasbourg, Strasbourg, France.,Faculty of Medicine, Federation of Translational Medicine (FMTS), Strasbourg, France
| |
Collapse
|
14
|
Renaud-Picard B, Gallais F, Riou M, Zouzou A, Porzio M, Kessler R. Delayed pulmonary abscess following COVID-19 pneumonia: A case report. Respir Med Res 2020; 78:100776. [PMID: 32623310 PMCID: PMC7301784 DOI: 10.1016/j.resmer.2020.100776] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2020] [Revised: 06/04/2020] [Accepted: 06/07/2020] [Indexed: 12/03/2022]
Affiliation(s)
- B Renaud-Picard
- Department of respirology and Strasbourg Lung Transplant Program, Nouvel hôpital civil, University Hospital of Strasbourg, 1, place de l'Hôpital, 67000 Strasbourg, France.
| | - F Gallais
- Laboratory of Virology, University Hospital of Strasbourg, 1, place de l'Hôpital, 67000 Strasbourg, France
| | - M Riou
- Department of respirology and Strasbourg Lung Transplant Program, Nouvel hôpital civil, University Hospital of Strasbourg, 1, place de l'Hôpital, 67000 Strasbourg, France
| | - A Zouzou
- Department of respirology and Strasbourg Lung Transplant Program, Nouvel hôpital civil, University Hospital of Strasbourg, 1, place de l'Hôpital, 67000 Strasbourg, France
| | - M Porzio
- Department of respirology and Strasbourg Lung Transplant Program, Nouvel hôpital civil, University Hospital of Strasbourg, 1, place de l'Hôpital, 67000 Strasbourg, France
| | - R Kessler
- Department of respirology and Strasbourg Lung Transplant Program, Nouvel hôpital civil, University Hospital of Strasbourg, 1, place de l'Hôpital, 67000 Strasbourg, France
| |
Collapse
|
15
|
Virot E, Marcot C, Vergnon JM, Matau C, Porzio M, Kessler R. Airway stent current practices evaluation: Survey among French bronchoscopy practitioners. Respir Med Res 2020; 77:89-94. [PMID: 32492650 DOI: 10.1016/j.resmer.2020.02.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2019] [Revised: 01/14/2020] [Accepted: 02/14/2020] [Indexed: 11/26/2022]
Abstract
BACKGROUND Airway stenting (AS) is performed for the treatment of benign or malignant central airway stenosis. In France, more than 30 centers practice AS. The aim of this survey was to evaluate the current practice around airway stenting among French bronchoscopy practitioners. METHOD We performed an online survey sent to the GELF group (Groupe d'Endoscopie de Langue Française) mailing list. The first part comprised 10 questions about the different attitudes before AS and the second part included 10 questions about the management after AS. RESULTS Thirty-six participants answered to the first part of the questionnaire and thirty-three to the second. There were some similarities, for example the absence of prophylactic antibiotic treatment before procedure (86%), use of saline nebulization, and removing or replacing the airway stent in case of persistent chest congestion or infection (73%). We also noted an important heterogeneity of the practices with several differences concerning systematic endoscopic control, bacteriological sampling before procedure (44%) and systematically AS replacement. CONCLUSION This survey shows that AS management in France varies between practitioners. Respondents agreed on a few points, but disagreed on several important aspects of the management. These results emphasize the need of expert recommendations to improve AS management.
Collapse
Affiliation(s)
- E Virot
- Respiratory Disease Department, Strasbourg University Hospital, Strasbourg, France.
| | - C Marcot
- Respiratory Disease Department, Strasbourg University Hospital, Strasbourg, France
| | - J-M Vergnon
- Department of Pulmonology, University Hospital of Saint-Étienne, 42000 Saint-Étienne, France
| | - C Matau
- Respiratory Disease Department, Strasbourg University Hospital, Strasbourg, France
| | - M Porzio
- Respiratory Disease Department, Strasbourg University Hospital, Strasbourg, France
| | - R Kessler
- Respiratory Disease Department, Strasbourg University Hospital, Strasbourg, France
| | | |
Collapse
|
16
|
Semple A, Clark T, Allen NM, Krishnananthan T, Nwokoro C, Girodon E, Porzio M, Herzig M. Identification of a novel cystic fibrosis mutation in three patients of South Asian descent. Clin Respir J 2020; 14:586-588. [PMID: 32043836 DOI: 10.1111/crj.13163] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/10/2019] [Accepted: 02/08/2020] [Indexed: 11/29/2022]
Abstract
INTRODUCTION The cystic fibrosis (CF) clinical profile and associated CFTR mutation spectrum is poorly understood in the South Asian population. This is likely due to the lack of diagnostic resources and the absence of a centralised CF database and screening programme, despite a relatively large proportion of the global population. METHODS Following identification of a previously unreported CFTR mutation (c.2805_2810delinsTCAGA; p.(Pro936Ginfs*6)) in a newly diagnosed patient of Indian descent, we interrogated national registries for other cases. RESULTS We identified three European-born subjects of South Asian descent with CF due to a novel CFTR mutation. All three subjects presented in infancy and each had a severe phenotype with intestinal complications as a presenting feature. Two subjects were diagnosed prior to the advent of universal screening. Preliminary genetic screening failed to identify the causative mutation in all three patients. CONCLUSION Our work highlights the value of extended or targeted genotyping in selected populations. It also demonstrates the benefit of routine collaboration between national registries. This will promote the identification of novel mutations; leading to greater understanding of genotype-phenotype associations, improved individual prognostication and ultimately the improved availability of novel precision therapies. This collaboration is essential if we are to achieve health equality for people with CF living in resource-limited settings.
Collapse
Affiliation(s)
- Aisling Semple
- Department of Paediatrics, National University of Ireland Galway, Ireland.,Department of Paediatrics, Galway University Hospital, Ireland
| | - Tara Clark
- Department of Genetics Counselling, Children's Health Ireland at Crumlin, Dublin 12, Ireland
| | - Nicholas M Allen
- Department of Paediatrics, National University of Ireland Galway, Ireland.,Department of Paediatrics, Galway University Hospital, Ireland
| | - Thanuja Krishnananthan
- Department of Paediatric Respiratory Medicine, Royal London Children's Hospital, London, UK
| | - Chinedu Nwokoro
- Department of Paediatric Respiratory Medicine, Royal London Children's Hospital, London, UK
| | - Emmanuelle Girodon
- Molecular Genetics Laboratory, Cochin Hospital, HUPC, APHP, Paris, France
| | - Michele Porzio
- Department of Respiratory Medicine, Nouvel Hôpital Civil, Strasbourg, France
| | - Mary Herzig
- Department of Paediatrics, National University of Ireland Galway, Ireland.,Department of Paediatrics, Galway University Hospital, Ireland
| |
Collapse
|
17
|
Renaud-Picard B, Vallière K, Toussaint J, Kreutter G, El-Habhab A, Kassem M, El-Ghazouani F, Olland A, Hirschi S, Porzio M, Chenard MP, Toti F, Kessler L, Kessler R. Epithelial-mesenchymal transition and membrane microparticles: Potential implications for bronchiolitis obliterans syndrome after lung transplantation. Transpl Immunol 2020; 59:101273. [PMID: 32097721 DOI: 10.1016/j.trim.2020.101273] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2019] [Revised: 02/20/2020] [Accepted: 02/20/2020] [Indexed: 02/07/2023]
Abstract
Long term survival post lung transplantation (LTx) is limited by the occurrence of bronchiolitis obliterans syndrome (BOS). One mechanism involved is the epithelial-mesenchymal transition (EMT). Membrane microparticles (MPs) are known to be involved in some respiratory diseases and in other organs allograft rejection episodes. We hypothesized that leukocyte-derived MPs likely contribute to EMT. To emphasize this physiological concept, our objectives were to: (1) confirm the presence of EMT on explanted lungs from patients who underwent a second LTx for BOS; 2) characterize circulating MPs in transplanted patients, with or without BOS; (3) evaluate in vitro the effect of monocyte-derived MPs in EMT of human bronchial epithelial cells. Our IHC analysis on explanted graft lungs revealed significant pathological signs of EMT with an inhomogeneous destruction of the bronchial epithelium, with decreased expression of the epithelial protein E-cadherin and increased expression of the mesenchymal protein Vimentin. The immunophenotyping of MPs demonstrated that the concentration of MPs carrying E-cadherin was lower in patients affected by BOS (p = .007). In vitro, monocyte-derived MPs produced with LPS were associated with decreased E-cadherin expression (p < .05) along with significant morphological and functional cell modifications. MPs may play a role in EMT onset in bronchial epithelium following LTx.
Collapse
Affiliation(s)
- Benjamin Renaud-Picard
- Department of Respiratory Medicine and Strasbourg Lung Transplant Program, University Hospital of Strasbourg, France; INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, University of Strasbourg, France; Faculty of Medicine, Federation of Translational Medicine (FMTS), Strasbourg, France.
| | - Kevin Vallière
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, University of Strasbourg, France
| | - Justine Toussaint
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, University of Strasbourg, France
| | - Guillaume Kreutter
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, University of Strasbourg, France
| | - Ali El-Habhab
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, University of Strasbourg, France
| | - Mohamad Kassem
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, University of Strasbourg, France
| | - Fatiha El-Ghazouani
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, University of Strasbourg, France
| | - Anne Olland
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, University of Strasbourg, France; Faculty of Medicine, Federation of Translational Medicine (FMTS), Strasbourg, France; Department of Thoracic Surgery and Strasbourg Lung Transplant Program, University Hospital of Strasbourg, France
| | - Sandrine Hirschi
- Department of Respiratory Medicine and Strasbourg Lung Transplant Program, University Hospital of Strasbourg, France
| | - Michele Porzio
- Department of Respiratory Medicine and Strasbourg Lung Transplant Program, University Hospital of Strasbourg, France
| | | | - Florence Toti
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, University of Strasbourg, France
| | - Laurence Kessler
- INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, University of Strasbourg, France; Faculty of Medicine, Federation of Translational Medicine (FMTS), Strasbourg, France
| | - Romain Kessler
- Department of Respiratory Medicine and Strasbourg Lung Transplant Program, University Hospital of Strasbourg, France; INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, University of Strasbourg, France; Faculty of Medicine, Federation of Translational Medicine (FMTS), Strasbourg, France
| |
Collapse
|
18
|
Burgel PR, Munck A, Durieu I, Chiron R, Mely L, Prevotat A, Murris-Espin M, Porzio M, Abely M, Reix P, Marguet C, Macey J, Sermet-Gaudelus I, Corvol H, Bui S, Lemonnier L, Dehillotte C, Da Silva J, Paillasseur JL, Hubert D, Mounard J, Poulet C, Rames C, Person C, Troussier F, Urban T, Dalphin ML, Dalphin JC, Pernet D, Richaud-Thiriez B, Bui S, Fayon M, Macey-Caro J, Campbell K, Laurans M, Borderon C, Heraud MC, Labbé A, Montcouquiol S, Bassinet L, Remus N, Fanton A, Houzel-Charavel A, Huet F, Perez-Martin S, Boldron-Ghaddar A, Scalbert M, Mely L, Camara B, Llerena C, Pin I, Quétant S, Cottereau A, Deschildre A, Gicquello A, Perez T, Stervinou-Wemeau L, Thumerelle C, Wallaert B, Wizla N, Languepin J, Ménétrey C, Dupuy-Grasset M, Bazus L, Buchs C, Jubin V, Werck-Gallois MC, Mainguy C, Perrin T, Reix P, Toutain-Rigolet A, Durieu I, Durupt S, Reynaud Q, Nove-Josserand R, Baravalle-Einaudi M, Coltey B, Dufeu N, Dubus JC, Stremler N, Caimmi D, Chiron R, Billon Y, Derelle J, Kieffer S, Pichon AS, Schweitzer C, Tatopoulos A, Abbes S, Bihouée T, Danner-Boucher I, David V, Haloun A, Tissot A, Leroy S, Bailly-Piccini C, Clément A, Corvol H, Tamalet A, Burgel PR, Honoré I, Hubert D, Kanaan R, Martin C, Bailly C, Chédevergne F, De Blic J, Fauroux B, Le Bourgeois M, Sermet-Gaudelus I, Delaisi B, Gérardin M, Munck A, Abély M, Ravoninjatovo B, Belleguic C, Desrues B, Brinchault G, Dagorne M, Deneuville E, Lefeuvre S, Dirou A, Le Bihan J, Ramel S, Dominique S, Marguet C, Payet A, Kessler R, Porzio M, Rosner V, Weiss L, de Miranda S, Grenet D, Hamid A, Picard C, Brémont F, Didier A, Labouret G, Mittaine M, Murris-Espin M, Têtu L, Cosson L, Giraut C, Henriet AC, Mankikian J, Marchand S, Hugé S, Storni V, Coirier-Duet E. Real-Life Safety and Effectiveness of Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis. Am J Respir Crit Care Med 2020; 201:188-197. [DOI: 10.1164/rccm.201906-1227oc] [Citation(s) in RCA: 61] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Affiliation(s)
- Pierre-Régis Burgel
- Université de Paris, Institut Cochin, INSERM U1016, Paris, France
- Respiratory Medicine and National Reference Cystic Fibrosis Reference Center, Cochin Hospital, Assistance Publique–Hôpitaux de Paris (AP-HP), Paris, France
- ERN-Lung CF Network
| | - Anne Munck
- Hôpital Robert Debré, AP-HP, Paris, France
| | - Isabelle Durieu
- ERN-Lung CF Network
- Centre de Référence Adulte de la Mucoviscidose, Service de Médecine Interne, Hospices Civils de Lyon, Pierre Bénite, France
- Université de Lyon, Équipe d’Accueil Health Services and Performance Research (HESPER) 7425, Lyon, France
| | - Raphaël Chiron
- Cystic Fibrosis Center, Hôpital Arnaud de Villeneuve, Centre Hospitalier Universitaire de Montpellier, Université de Montpellier, Montpellier, France
| | - Laurent Mely
- Hôpital Renée Sabran, Cystic Fibrosis Center, Giens, France
| | - Anne Prevotat
- CHU-Lille, Cystic Fibrosis Center, Service de Pneumologie et Immuno-allergologie, Hôpital Calmette and Université de Lille, Lille, France
| | - Marlene Murris-Espin
- Cystic Fibrosis Center, Service de Pneumologie, Pôle des Voies Respiratoires, Hôpital Larrey, CHU de Toulouse, Toulouse, France
| | - Michele Porzio
- Department of Respiratory Medicine and Cystic Fibrosis Center, Federation of Translational Medicine of Strasbourg, University Hospitals, Strasbourg, France
| | - Michel Abely
- Department of Pediatrics A and Cystic Fibrosis Center, American Memorial Hospital, Reims, France
| | - Philippe Reix
- UMR 5558 CNRS, Equipe EMET, Université Claude Bernard Lyon 1, Lyon, France
- Cystic Fibrosis Center, Hospices Civils de Lyon, Lyon, France
| | - Christophe Marguet
- Pediatric Respiratory Disease and Cystic Fibrosis Center, Hospital, UNIROUEN, INSERM EA 2656, Rouen University Hospital, Université de Normandie, Rouen, France
| | - Julie Macey
- Respiratory Medicine and Cystic Fibrosis Center, CHU de Bordeaux, Bordeaux, France
| | - Isabelle Sermet-Gaudelus
- ERN-Lung CF Network
- Pediatric Respiratory Disease and Cystic Fibrosis Center, National Reference Cystic Fibrosis Reference Center, Hôpital Necker Enfants Malades, Paris France
- INSERM U 1151, Institut Necker Enfants Malades, Paris, France
| | - Harriet Corvol
- Sorbonne Université, Centre de Recherche Saint-Antoine, Paris, France
- Pediatric Respiratory Disease and Cystic Fibrosis Center, Hôpital Trousseau, AP-HP, Paris, France
| | - Stéphanie Bui
- Pediatric Respiratory Disease and Cystic Fibrosis Center and CIC 1401, CHU de Bordeaux, Bordeaux, France
| | | | | | - Jennifer Da Silva
- Université de Paris, Institut Cochin, INSERM U1016, Paris, France
- ERN-Lung CF Network
- URC-CIC Paris Descartes Necker Cochin, AP-HP, Hôpital Cochin, Paris, France; and
| | | | - Dominique Hubert
- Respiratory Medicine and National Reference Cystic Fibrosis Reference Center, Cochin Hospital, Assistance Publique–Hôpitaux de Paris (AP-HP), Paris, France
- ERN-Lung CF Network
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Riou M, Renaud-Picard B, Munch M, Lefebvre F, Baltzinger P, Porzio M, Hirschi S, Dégot T, Schuller A, Santelmo N, Reeb J, Olland A, Falcoz PE, Massard G, Kessler L, Kessler R. Organized Management of Diabetes Mellitus in Lung Transplantation: Study of Glycemic Control and Patient Survival in a Single Center. Transplant Proc 2019; 51:3375-3384. [DOI: 10.1016/j.transproceed.2019.07.019] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2018] [Revised: 05/31/2019] [Accepted: 07/09/2019] [Indexed: 12/27/2022]
|
20
|
Kassegne L, Degot T, Morel O, Reeb J, Carmona A, Schuller A, Hirschi S, Porzio M, Martin G, Riou M, Kessler R, Renaud-Picard B. Acute Cardiac Failure Due to Takotsubo Cardiomyopathy Secondary to a Phone Call for Lung Transplantation: A Case Report. Transplant Proc 2019; 51:3167-3170. [PMID: 31619342 DOI: 10.1016/j.transproceed.2019.07.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2019] [Accepted: 07/09/2019] [Indexed: 11/19/2022]
Abstract
Lung transplantation is a therapeutic option for certain end-stage lung diseases. The phone call for lung transplantation is a major event in the life of these patients; as a result, it can generate significant stress. We herein present the case of a 58-year-old female patient with end-stage chronic obstructive pulmonary disease (COPD) who, while on the lung transplantation waiting list, received such a call. Complete transplant work-up, including cardiac tests undertaken shortly before, had revealed no contraindication to lung transplantation. She was admitted with severe acute respiratory failure, and her extensive work-up was compatible with pulmonary edema due to takotsubo cardiomyopathy. The lung transplantation was thus cancelled, owing to the patient's health condition and the poor quality of the graft as well. The patient stayed in the intensive care unit for several days, requiring noninvasive ventilation. The left ventricular function recovered completely within 10 days postdiagnosis, and the patient was discharged 13 days after her admission. The patient was transplanted 1 month thereafter, without any particular problems; she is currently, 8 months post-transplantation, in good condition. In the given case, the call for lung transplantation could have generated emotional stress severe enough to lead to takotsubo cardiomyopathy.
Collapse
Affiliation(s)
- L Kassegne
- Service de Pneumologie, Groupe de Transplantation Pulmonaire de Strasbourg, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
| | - T Degot
- Service de Pneumologie, Groupe de Transplantation Pulmonaire de Strasbourg, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - O Morel
- Service de Cardiologie, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - J Reeb
- Service de Chirurgie Thoracique, Clinique Rhéna, Strasbourg, France
| | - A Carmona
- Service de Cardiologie, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - A Schuller
- Service de Pneumologie, Groupe de Transplantation Pulmonaire de Strasbourg, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - S Hirschi
- Service de Pneumologie, Groupe de Transplantation Pulmonaire de Strasbourg, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - M Porzio
- Service de Pneumologie, Groupe de Transplantation Pulmonaire de Strasbourg, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - G Martin
- Service de Pneumologie, Groupe de Transplantation Pulmonaire de Strasbourg, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - M Riou
- Service de Pneumologie, Groupe de Transplantation Pulmonaire de Strasbourg, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - R Kessler
- Service de Pneumologie, Groupe de Transplantation Pulmonaire de Strasbourg, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - B Renaud-Picard
- Service de Pneumologie, Groupe de Transplantation Pulmonaire de Strasbourg, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| |
Collapse
|
21
|
Mazzetta A, Porzio M, Riou M, Coiffard B, Olland A, Dégot T, Seitlinger J, Massard G, Renaud-Picard B, Kessler R. Patients Treated for Central Airway Stenosis After Lung Transplantation Have Persistent Airflow Limitation. Ann Transplant 2019; 24:84-92. [PMID: 30760698 PMCID: PMC6383442 DOI: 10.12659/aot.911923] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Background Although central airway stenosis (CAS) is a common complication after lung transplantation, its consequences have been poorly evaluated. The objective of our study was to evaluate the impact of CAS on lung function after lung transplantation. Material/Methods All lung transplant recipients from June 2009 to August 2014 in a single center (Strasbourg, France) were retrospectively reviewed. Results A total of 191 lung transplantations were performed: 175 bilateral, 15 single, and 1 heart-lung transplantation. Of the 161 bilateral lung-transplanted patients who survived >3 months, 22 (13.6%) developed CAS requiring endobronchial treatment. All these patients were treated by endoscopic balloon dilatation, and 9 additionally needed endobronchial stents. Respiratory function tests demonstrated persistent obstructive ventilatory pattern despite endoscopic treatment in recipients with CAS compared to those without CAS at 6, 12, and 18 months post-transplant. At 18 months, CAS patients had significantly lower post-transplant FEV1 (1.96±0.60 L versus 2.57±0.76 L, p=0.001) and FEV1/FVC (61±14% versus 81±13%, p<0.001). The percentage of patients hospitalized for respiratory infections and number of hospital days were significantly increased in recipients with CAS (20 [91%] versus 92 [66%] p=0.036, and 144±110 days versus 103±83 days p=0.042, respectively). Survival in transplant recipients did not significantly differ between those with CAS and those without. Conclusions CAS after lung transplantation was not associated with worse survival, but it did have a significant and persistent effect on lung function, and was associated with increased rate of respiratory infection.
Collapse
Affiliation(s)
- Andrea Mazzetta
- Department of Respiratory Medicine, Federation of Translational Medicine of Strasbourg (FMTS), University Hospitals, Strasbourg, France
| | - Michele Porzio
- Department of Respiratory Medicine, Federation of Translational Medicine of Strasbourg (FMTS), University Hospitals, Strasbourg, France
| | - Marianne Riou
- Department of Respiratory Medicine, Federation of Translational Medicine of Strasbourg (FMTS), University Hospitals, Strasbourg, France
| | - Benjamin Coiffard
- Department of Respiratory Medicine, Federation of Translational Medicine of Strasbourg (FMTS), University Hospitals, Strasbourg, France
| | - Anne Olland
- Department of Thoracic Surgery, University Hospitals, Strasbourg, France.,EA 7293 Vascular and Tissue Stress in Transplantation, UNISTRA, Strasbourg, France
| | - Tristan Dégot
- Department of Respiratory Medicine, Federation of Translational Medicine of Strasbourg (FMTS), University Hospitals, Strasbourg, France
| | - Joseph Seitlinger
- Department of Thoracic Surgery, University Hospitals, Strasbourg, France
| | - Gilbert Massard
- Department of Thoracic Surgery, University Hospitals, Strasbourg, France.,EA 7293 Vascular and Tissue Stress in Transplantation, UNISTRA, Strasbourg, France
| | - Benjamin Renaud-Picard
- Department of Respiratory Medicine, Federation of Translational Medicine of Strasbourg (FMTS), University Hospitals, Strasbourg, France.,EA 7293 Vascular and Tissue Stress in Transplantation, UNISTRA, Strasbourg, France
| | - Romain Kessler
- Department of Respiratory Medicine, Federation of Translational Medicine of Strasbourg (FMTS), University Hospitals, Strasbourg, France.,EA 7293 Vascular and Tissue Stress in Transplantation, UNISTRA, Strasbourg, France
| |
Collapse
|
22
|
Chatron E, Misgault B, Porzio M, Kessler L, Kessler R. Évaluation des anomalies de la tolérance du glucose chez des patients atteints de mucoviscidose, homozygotes pour la mutation Delta F508 du CFTR, traités par Ivacaftor–Lumacaftor. Rev Mal Respir 2019. [DOI: 10.1016/j.rmr.2018.10.043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
23
|
Chatron E, Dégot T, Salvaterra E, Dumazet A, Porzio M, Hirschi S, Schuller A, Massard G, Renaud-Picard B, Kessler R. Lung cancer after lung transplantation: An analysis of 25 years of experience in a single institution. Clin Transplant 2018; 33:e13446. [DOI: 10.1111/ctr.13446] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2018] [Revised: 10/26/2018] [Accepted: 11/04/2018] [Indexed: 12/11/2022]
Affiliation(s)
- Eva Chatron
- Groupe de transplantation pulmonaire; Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil; Strasbourg Cedex France
| | - Tristan Dégot
- Groupe de transplantation pulmonaire; Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil; Strasbourg Cedex France
| | - Elena Salvaterra
- Groupe de transplantation pulmonaire; Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil; Strasbourg Cedex France
| | - Antoine Dumazet
- Groupe de transplantation pulmonaire; Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil; Strasbourg Cedex France
| | - Michele Porzio
- Groupe de transplantation pulmonaire; Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil; Strasbourg Cedex France
| | - Sandrine Hirschi
- Groupe de transplantation pulmonaire; Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil; Strasbourg Cedex France
| | - Armelle Schuller
- Groupe de transplantation pulmonaire; Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil; Strasbourg Cedex France
| | - Gilbert Massard
- Groupe de transplantation pulmonaire; Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil; Strasbourg Cedex France
| | - Benjamin Renaud-Picard
- Groupe de transplantation pulmonaire; Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil; Strasbourg Cedex France
| | - Romain Kessler
- Groupe de transplantation pulmonaire; Hôpitaux Universitaires de Strasbourg, Nouvel Hôpital Civil; Strasbourg Cedex France
| |
Collapse
|
24
|
Zucchi E, Porzio M, Mon G, Coloberti F. 278. Scatter correction software for grid-less acquisition in digital mammography – Statistical approach on a visual grading phantom study. Phys Med 2018. [DOI: 10.1016/j.ejmp.2018.04.288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
25
|
Wagner C, Porzio M, Olland A, Reeb J, Greget M, Grenet D, Bouilloud F, Bonnette P, Berney T, Javelot Jacquelin C, Baltzinger P, Kessler R, Kessler L. WS19.6 Feasibility and efficacy of combined lung and pancreatic islet transplantation in Cystic Fibrosis-Related Diabetes: a pilot study. J Cyst Fibros 2018. [DOI: 10.1016/s1569-1993(18)30231-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
26
|
Meloni F, Rossi E, Inghilleri S, Porzio M, Zorzetto M, Kessler R, Morbini P. miRNA Dysregulation in Chronic Lung Allograft Rejection. A Computational, Quantitative and In Situ Analysis. J Heart Lung Transplant 2018. [DOI: 10.1016/j.healun.2018.01.776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
27
|
Porzio M, Mazzetta A, Riou M, Olland A, Degot T, Seiltinger J, Kessler R. Limitation persistante des débits aériens chez les patients avec sténoses bronchiques après greffe pulmonaire. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
28
|
Leroux J, Schuller A, Degot T, Porzio M, Renaud-Picard B, Bohbot A, Kessler R, Hirschi S. Traitement du syndrome de bronchiolite oblitérante en greffe pulmonaire par photophérèse extracorporelle : expérience monocentrique. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.335] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
29
|
Porzio M, Zapata E, Canuet M, Kessler R. Eosinophiles et exacerbation de BPCO. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.456] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
30
|
Chatron E, Degot T, Salvaterra E, Dumazet A, Porzio M, Renaud-Picard B, Hirschi S, Schuller A, Massard G, Kessler R. Cancer du poumon et transplantation pulmonaire. À propos de l’expérience du centre de Strasbourg. Rev Mal Respir 2018. [DOI: 10.1016/j.rmr.2017.10.033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
31
|
Gschwend A, Dégot T, Denis J, Sabou AM, Jeung MY, Zapata E, Porzio M, Renaud-Picard B, Herbrecht R, Kessler R. Brain abscesses caused by Cladophialophora bantiana
in a lung transplant patient: A case report and review of the literature. Transpl Infect Dis 2017; 19. [DOI: 10.1111/tid.12787] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2017] [Revised: 05/30/2017] [Accepted: 06/29/2017] [Indexed: 11/28/2022]
Affiliation(s)
- Anthony Gschwend
- Service de Pneumologie; Nouvel Hôpital Civil; Hôpitaux Universitaires de Strasbourg; Fédération de Médecine Translationnelle (FMTS); Strasbourg France
| | - Tristan Dégot
- Service de Pneumologie; Nouvel Hôpital Civil; Hôpitaux Universitaires de Strasbourg; Fédération de Médecine Translationnelle (FMTS); Strasbourg France
| | - Julie Denis
- Laboratoire de Parasitologie et Mycologie Médicale; Plateau Technique de Microbiologie; Hôpitaux Universitaires de Strasbourg; Strasbourg France
- Institut de Parasitologie et de Pathologie Tropicale; EA 7292; Fédération de Médecine Translationnelle (FMTS); Université de Strasbourg; Strasbourg France
| | - Alina M. Sabou
- Laboratoire de Parasitologie et Mycologie Médicale; Plateau Technique de Microbiologie; Hôpitaux Universitaires de Strasbourg; Strasbourg France
- Institut de Parasitologie et de Pathologie Tropicale; EA 7292; Fédération de Médecine Translationnelle (FMTS); Université de Strasbourg; Strasbourg France
| | - Mi Young Jeung
- Service de Radiologie B; Nouvel Hôpital Civil; Hôpitaux Universitaires de Strasbourg; Strasbourg France
| | - Emilie Zapata
- Service de Pneumologie; Nouvel Hôpital Civil; Hôpitaux Universitaires de Strasbourg; Fédération de Médecine Translationnelle (FMTS); Strasbourg France
| | - Michele Porzio
- Service de Pneumologie; Nouvel Hôpital Civil; Hôpitaux Universitaires de Strasbourg; Fédération de Médecine Translationnelle (FMTS); Strasbourg France
| | - Benjamin Renaud-Picard
- Service de Pneumologie; Nouvel Hôpital Civil; Hôpitaux Universitaires de Strasbourg; Fédération de Médecine Translationnelle (FMTS); Strasbourg France
- EA 7293 Stress Vasculaire et Tissulaire en Transplantation; Université de Strasbourg; Strasbourg France
| | - Raoul Herbrecht
- Service d'Hématologie et d'Oncologie; Hôpital de Hautepierre; Hôpitaux Universitaires de Strasbourg; Strasbourg France
| | - Romain Kessler
- Service de Pneumologie; Nouvel Hôpital Civil; Hôpitaux Universitaires de Strasbourg; Fédération de Médecine Translationnelle (FMTS); Strasbourg France
- EA 7293 Stress Vasculaire et Tissulaire en Transplantation; Université de Strasbourg; Strasbourg France
| |
Collapse
|
32
|
El Khoury H, Mazzetta A, Porzio M, Kessler R. Les traitements de fond de la BPCO perdent-ils de l’efficacité avec le temps ? Rev Mal Respir 2017; 34:591-593. [DOI: 10.1016/j.rmr.2016.08.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2016] [Accepted: 08/17/2016] [Indexed: 10/20/2022]
|
33
|
Porzio M, Coloberti F, Zucchi E. Iterative method for CT system: Dose reduction and quantitative analysis of image quality improvement. Phys Med 2016. [DOI: 10.1016/j.ejmp.2016.01.301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
34
|
Riou M, Baltzinger P, Porzio M, Degot T, Hirschi S, Kessler L, Kessler R. Effet du diabète sur la survie et l’hospitalisation après transplantation pulmonaire. Rev Mal Respir 2016. [DOI: 10.1016/j.rmr.2015.10.435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
35
|
Barry Mamadou A, Porzio M, Canuet M, Kessler L, Kessler R. Diabète et hospitalisation pour exacerbation de BPCO. Rev Mal Respir 2016. [DOI: 10.1016/j.rmr.2015.10.381] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
36
|
Capuano D, Cova E, Miserere S, Piloni D, Porzio M, Oggionni T, Meloni F. Uteroglobin Protective Role in CLAD, from Proteomic to In Vitro Biological Activity. J Heart Lung Transplant 2013. [DOI: 10.1016/j.healun.2013.01.1024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
37
|
Smith A, Kim G, Keung B, Allen B, Porzio M, Latner C, Singleton J. The Reliability of Corneal Nerve Fiber Assessment Using Corneal Confocal Microscopy (P03.203). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.p03.203] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
38
|
Cheng HL, Dauch J, Porzio M, Yanik B, Hsieh W, Smith A, Singleton J, Feldman E. Useful Biomarkers for the Diagnosis of Painful Diabetic Neuropathy (S07.003). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.s07.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
39
|
Cheng HL, Dauch J, Porzio M, Yanik B, Hsieh W, Smith A, Singleton J, Feldman E. Useful Biomarkers for the Diagnosis of Painful Diabetic Neuropathy (IN1-1.004). Neurology 2012. [DOI: 10.1212/wnl.78.1_meetingabstracts.in1-1.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
40
|
Affiliation(s)
- G. Bajo
- a Istituto di Chimica delíe Macromolecole , Via E. Bassini, 15 20133 , Milano , Italy
| | - A. Bolognesi
- a Istituto di Chimica delíe Macromolecole , Via E. Bassini, 15 20133 , Milano , Italy
| | - S. Destri
- a Istituto di Chimica delíe Macromolecole , Via E. Bassini, 15 20133 , Milano , Italy
| | - Z. Geng
- a Istituto di Chimica delíe Macromolecole , Via E. Bassini, 15 20133 , Milano , Italy
| | - M. Porzio
- a Istituto di Chimica delíe Macromolecole , Via E. Bassini, 15 20133 , Milano , Italy
| |
Collapse
|
41
|
Del Gaudio T, Distasi M, Porzio M, Miragliotta G. Isolation and antibiotic resistance of Ureaplasma spp. isolated from urogenital specimen between 2002 to 2007. Microbiol Med 2009. [DOI: 10.4081/mm.2009.2550] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
42
|
Abstract
Carrier compositions based on blends of various octenylsuccinic acid anhydride (OSAN)-modified starches were utilized in the glass encapsulation of flavours by means of melt extrusion and spray drying. Dextrinized, acid and enzymatically hydrolysed OSAN starches were used in various combinations. Processing parameters were optimized for desirable physical chemical and functional properties of the encapsulating compositions. One key property in the optimization of the extrusion process was setting rate of the exiting melt into a glass. Glassy states of identical spray-dried and extruded compositions were characterized by MDSC for glass transition temperature(s), heat capacity change and enthalpy relaxation. Flavour retention, surface flavour, moisture, particle density and flavour particle size distribution were also measured and compared for the extruded and spray-dried compositions. In addition, elastic recovery and caking were evaluated for extruded compositions. The glass transition parameters were correlated directly or indirectly with most of the physical properties of encapsulating compositions, especially flavour retention, surface flavour and caking. In extruded compositions, two phases were revealed by the presence of two glass transitions, whereas spray-dried compositions showed only one broad glass transition.
Collapse
Affiliation(s)
- D Zasypkin
- McCormick and Co., Technical Innovation Center, 204 Wight Avenue, Hunt Valley, MD 21031, USA
| | | |
Collapse
|
43
|
Del Gaudio T, Fuzio P, Porzio M, Lacerenza S, Pirronti A, Del Prete R, Miragliotta G. FREQUENZA DI ISOLAMENTO DI A. CALCOACETICUS - BAUMANNII COMPLEX IN UN REPARTO DI RIANIMAZIONE. Microbiol Med 2006. [DOI: 10.4081/mm.2006.3138] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
44
|
Del Gaudio T, Porzio M, Tarricone N, Mosca A, Miragliotta G. USO DI UN AGAR SCREEN PER L’IDENTIFICAZIONE DI MRSA. Microbiol Med 2005. [DOI: 10.4081/mm.2005.3503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
45
|
Stasi M, Giordanengo S, Cirio R, Boriano A, Bourhaleb F, Cornelius I, Donetti M, Garelli E, Gomola I, Marchetto F, Porzio M, Sanz Freire CJ, Sardo A, Peroni C. D-IMRT verification with a 2D pixel ionization chamber: dosimetric and clinical results in head and neck cancer. Phys Med Biol 2005; 50:4681-94. [PMID: 16177497 DOI: 10.1088/0031-9155/50/19/017] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Dynamic intensity-modulated radiotherapy (D-IMRT) using the sliding-window technique is currently applied for selected treatments of head and neck cancer at Institute for Cancer Research and Treatment of Candiolo (Turin, Italy). In the present work, a PiXel-segmented ionization Chamber (PXC) has been used for the verification of 19 fields used for four different head and neck cancers. The device consists of a 32x32 matrix of 1024 parallel-plate ionization chambers arranged in a square of 24x24 cm2 area. Each chamber has 0.4 cm diameter and 0.55 cm height; a distance of 0.75 cm separates the centre of adjacent chambers. The sensitive volume of each single ionization chamber is 0.07 cm3. Each of the 1024 independent ionization chambers is read out with a custom microelectronics chip.The output factors in water obtained with the PXC at a depth of 10 cm were compared to other detectors and the maximum difference was 1.9% for field sizes down to 3x3 cm2. Beam profiles for different field dimensions were measured with the PXC and two other types of ionization chambers; the maximum distance to agreement (DTA) in the 20-80% penumbra region of a 3x3 cm2 field was 0.09 cm. The leaf speed of the multileaf collimator was varied between 0.07 and 2 cm s-1 and the detector response was constant to better than 0.6%. The behaviour of the PXC was measured while varying the dose rate between 0.21 and 1.21 Gy min-1; the mean difference was 0.50% and the maximum difference was 0.96%. Using fields obtained with an enhanced dynamic wedge and a staircase-like (step) IMRT field, the PXC has been tested for simple 1D modulated beams; comparison with film gave a maximum DTA of 0.12 cm. The PXC was then used to check four different IMRT plans for head and neck cancer treatment: cervical chordoma, parotid, ethmoid and skull base. In the comparison of the PXC versus film and PXC versus treatment planning system, the number of pixels with gamma parameter<or=1 was 97.7% and 97.6%, respectively.
Collapse
Affiliation(s)
- M Stasi
- Institute for Cancer Research and Treatment (IRCC), Candiolo and A.S.O. Ordine Maurizano, Torino, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Del Gaudio T, D’Alagni M, Porzio M, Ricciardi E, Tarricone N, Mosca A, Miragliotta G. UTILITA’ DEL PAR-TEST NELL’INTERPRETAZIONE DELL’URINOCOLTURA. Microbiol Med 2004. [DOI: 10.4081/mm.2004.3913] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
47
|
Del Gaudio T, Porzio M, Ricciardi E, Miragliotta G. PATOGENI ENTERICI ISOLATI DA FECI DI PAZIENTI SINTOMATICI IN UNA POPOLAZIONE DEL NORD-BARESE NEL PERIODO GENNAIO 1996 - DICEMBRE 2002. Microbiol Med 2003. [DOI: 10.4081/mm.2003.4234] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
48
|
Del Gaudio T, Porzio M, Miragliotta G. POSSIBILITÀ DI VALUTAZIONE MICROBIOLOGICA PRECOCE DI BATTERIEMIA. Microbiol Med 2003. [DOI: 10.4081/mm.2003.4278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
49
|
Barone A, Porzio M, Ramaglia L, Sbordone L. [Implants in partially edentulous patients with history of periodontal disease]. Minerva Stomatol 2000; 49:87-91. [PMID: 20047206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
BACKGROUND Microbiota associated with periodontal diseases were also associated with periimplant diseases. The purpose of this study was to determine the clinical status and composition of subgingival microbiota of implants and natural teeth in a group of partially edentulous patients with history of periodontal disease. METHODS 38 partially edentulous patients with history of periodontal disease, treated with dental implants, were selected for this study. Patients selected for the study were in good health condition and did not take any antibiotics in the last six months. One year after second stage surgery a total of 72 implants and 38 teeth underwent clinical and microbiological examination. Clinical parameters were PD, PAL, PI and GI. Subgingival plaque samples were analyzed by dark-field microscopy and cultural analysis. RESULTS Clinical parameters didn't show any significant differences between periodontal and periimplant tissues. Dark-field microscopic examination showed higher prevalence of rods and spirochetes around implants than around teeth. There were no differences detected by cultural examination in the subgingival microbiota at peri-implant and periodontal sites. CONCLUSIONS Findings from this study showed no differences between implants and teeth in partially edentulous patients with history of periodontal disease one year after second stage surgery. Implants were colonized by microbiota similar to that observed around teeth and were well-maintained in patients with a history of periodontitis.
Collapse
Affiliation(s)
- A Barone
- Università degli Studi-Pisa, Facoltà di Medicina e Chirurgia, Cattedra di Parodontologia
| | | | | | | |
Collapse
|
50
|
Ballarè M, Campanini M, Airoldi G, Zaccala G, Bertoncelli MC, Cornaglia G, Porzio M, Monteverde A. Hepatotoxicity of hydroxy-methyl-glutaryl-coenzyme A reductase inhibitors. MINERVA GASTROENTERO 1992; 38:41-4. [PMID: 1520752] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The first clinical studies on hydroxy-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors reported a low incidence of liver toxicity. The personal observation of a case of simvastatin-induced acute cholestatic hepatitis prompted us to evaluate the true incidence of hepatic side effects of these drugs in a large Italian population. One hundred patients taking simvastatin and ninety patients treated with pravastatin were followed-up six months with periodical evaluation of serum lipid levels and liver function test. In 5% of simvastatin-treated patients and 4.5% of pravastatin-treated patients significant liver toxicity was observed, which required drug discontinuation. The mechanism of liver damage was direct, idiosyncratic, but immunological features of drug toxicity could be hypothesized in one patient.
Collapse
Affiliation(s)
- M Ballarè
- Divisione di Medicina Generale II, Ospedale Maggiore di Novara
| | | | | | | | | | | | | | | |
Collapse
|